The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jul. 25, 7:02 PM

Slide #21. Auspex Pharmaceuticals, Inc. Secondary Offering

Company: Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX)
Date announced: 7/11/2014
Shares Offered: 3,150,000
Date of Pricing: 7/11/2014
Price Per Share: $19.25
Secondary Offering Details: Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced today the pricing of its underwritten public offering of 3,150,000 shares of common stock at a price to the public of $19.25 per share. The gross proceeds to Auspex from this offering are expected to be approximately $60.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Auspex. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 472,500 shares of common stock.

Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases, which are rare diseases that affect fewer than 200,000 people in the United States and that may often present unmet medical needs. Co.'s pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease, an orphan disease, and tardive dyskinesia and Tourette syndrome, subsets of either of which may be deemed to be orphan diseases, as well as other orphan indications.
Open the ASPX Page at The Online Investor »

Company Name:  Auspex Pharmaceuticals Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ASPX:  11
Total Market Value Held by ETFs:  $4.01M
Total Market Capitalization:  $479.00M
% of Market Cap. Held by ETFs:  0.84%

Open the ASPX Page at The Online Investor (in a new window) »

July 25, 2014    7:02 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
92nd percentile
(ranked higher than approx. 92% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.